BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, December 26, 2024
See today's BioWorld
Home
» In the clinic for Nov. 4, 2022
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
In the clinic for Nov. 4, 2022
Nov. 4, 2022
No Comments
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4D, Abeona, Actinium, Aelix, Albireo, Apeiron, Aramis, Arbutus, Ardelyx, Atea, Biontech, Biophytis, Blaze, Chinook, Clairvoyant, Compass, Daewoong, Emergent, G1, GSK, Inozyme, Lianbio, Madrigal, Neurocrine, Neurotech, Ose, Pfizer, Regenxbio, Regulus, Renovion, Rhythm, Rigel, Sagimet, Sonnet, Surface Oncology, Syndax, Theriva, Transgene, Uniqure, Vectivbio.
BioWorld
Briefs
In the clinic
Coronavirus